Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Fig. 1

Swimmers plot for progression-free survival according to RECIST central radiological review. Each bar represents one patient. Red arrows identify patients with absence of progression at the last radiological follow up. The vertical line represents the median progression-free survival for the whole series

Back to article page

Molecular Cancer

ISSN: 1476-4598